Patents by Inventor Aya Jakobovits

Aya Jakobovits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 24P4C12 PROTEINS
    Publication number: 20090175796
    Abstract: Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Application
    Filed: September 5, 2008
    Publication date: July 9, 2009
    Inventors: Arthur B. RAITANO, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Steven B. Kanner, Pia M. Challita-Eid, Xiao-chi Jia, Jean Gudas, Aya Jakobovits
  • 84P2A9: A PROSTATE AND TESTIS SPECIFIC PROTEIN HIGHLY EXPRESSED IN PROSTATE CANCER
    Publication number: 20090170191
    Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Application
    Filed: November 26, 2008
    Publication date: July 2, 2009
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Daniel E.H. Afar, Pia M. Challita-Eid, Elana Levin, Steve Chappell Mitchell, Rene S. Hubert
  • Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
    Publication number: 20090169476
    Abstract: A novel gene 08P1D4 (also designated STEAP-1) and its encoded protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Application
    Filed: October 12, 2006
    Publication date: July 2, 2009
    Inventors: Mary Faris, Wangmao Ge, Arthur B. Raitano, Pia M. Challita-Eid, Aya Jakobovits
  • 238P1B2 protein
    Patent number: 7553814
    Abstract: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: June 30, 2009
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Mary Faris, Rene S. Hubert, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20090162850
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Application
    Filed: September 22, 2008
    Publication date: June 25, 2009
    Applicant: AGENSYS, INC.
    Inventors: MARY FARIS, PIA M. CHALLITA-EID, RENE S. HUBERT, DANIEL E. H. AFAR, ARTHUR B. RAITANO, WANGMAO GE, ROBERT KENDALL MORRISON, KAREN JANE MEYRICK MORRISON, AYA JAKOBOVITS
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 184P1E2 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20090148854
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Application
    Filed: January 21, 2009
    Publication date: June 11, 2009
    Applicant: AGENSYS, INC.
    Inventors: Pia M. CHALLITA-EID, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Human antibodies derived from immunized xenomice
    Publication number: 20090149637
    Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.
    Type: Application
    Filed: August 8, 2007
    Publication date: June 11, 2009
    Inventors: Raju Kucherlapati, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
  • Antibodies and related molecules that bind to PSCA proteins
    Patent number: 7541442
    Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: June 2, 2009
    Assignee: Agensys, Inc.
    Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Pia M. Challita-Eid, Arthur B. Raitano
  • 103P2D6: tissue specific protein highly expressed in various cancers
    Patent number: 7534417
    Abstract: A novel gene (designated 103P2D6) and its encoded protein are described. 103P2D6 is not expressed in normal adult tissue, but is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in prostate cancer. 103P2D6 is also expressed in some fetal tissues, and in breast, bladder, lung, bone, colon, pancreatic, testicular, cervical and ovarian cancers. Consequently, 103P2D6 provides a diagnostic and/or therapeutic target for cancers, and the 103P2D6 gene or fragment thereof, or its encoded protein or a fragment thereof can be used to elicit an immune response.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: May 19, 2009
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Daniel E. H. Afar, Gazelle S. Rastegar, Steve Chappell Mitchell, Rene S. Hubert, Pia M. Challita-Eid, Mary Faris, Aya Jakobovits
  • PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF
    Publication number: 20090104631
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Application
    Filed: July 8, 2008
    Publication date: April 23, 2009
    Applicants: The Regents of the University of California, Agensys, Inc.
    Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
  • 84P2A9: a prostate and testis specific protein highly expressed in prostate cancer
    Patent number: 7510855
    Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: March 31, 2009
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Daniel E. H. Afar, Pia M. Challita-Eid, Elena Levin, Steve Chappell Mitchell, Rene S. Hubert
  • Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody
    Patent number: 7510840
    Abstract: A novel gene (designated 108P5H8) and its encoded protein, and variants thereof, are described wherein 108P5H8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 108P5H8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 108P5H8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: March 31, 2009
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Mary Faris, Daniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell, Elana Levin, Karen Jane Meyrick Morrison, Arthur B. Raitano, Aya Jakobovits
  • 36P6D5: secreted tumor antigen
    Patent number: 7507541
    Abstract: Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary and pancreas.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: March 24, 2009
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Aya Jakobovits, Mary Faris, Daniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell
  • NOVEL GENE UPREGULATED IN CANCERS OF THE PROSTATE
    Publication number: 20090074797
    Abstract: The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogeneous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 1, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein.
    Type: Application
    Filed: July 9, 2008
    Publication date: March 19, 2009
    Inventors: Daniel E. H. Afar, Arthur B. Raitano, Rene S. Hubert, Steve Chappell Mitchell, Aya Jakobovits
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 58P1D12 PROTEINS
    Publication number: 20090068098
    Abstract: Antibodies and molecules derived therefrom that bind to 58P1D12 protein and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.
    Type: Application
    Filed: August 20, 2008
    Publication date: March 12, 2009
    Inventors: Steven B. KANNER, Aya Jakobovits, Jean Gudas, Arthur B. Raitano, Robert Kendall Morrison, Pia M. Challita-Eid, Xiao-chi Jia
  • Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer
    Patent number: 7501502
    Abstract: A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: March 10, 2009
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Mary Faris, Rene S. Hubert, Daniel Afar, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
  • Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
    Patent number: 7494646
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: February 24, 2009
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • 121P1F1: A TISSUE SPECIFIC PROTEIN HIGHLY EXPRESSED IN VARIOUS CANCERS
    Publication number: 20090041756
    Abstract: A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides a diagnostic and/or therapeutic target for cancers, and the 121P1F1 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Application
    Filed: December 7, 2007
    Publication date: February 12, 2009
    Inventors: PIA M. CHALLITA-EID, RENE S. HUBERT, STEVEN CHAPPELL MITCHELL, ARTHUR B. RAITANO, MARY FARIS, DANIEL E.H. AFAR, AYA JAKOBOVITS
  • Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
    Patent number: 7488479
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: February 10, 2009
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Pia M. Challita-Eid, Rene S. Hubert, Daniel E. H. Afar, Arthur B. Raitano, Wangmao Ge, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Aya Jakobovits
  • PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer
    Patent number: 7485296
    Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: February 3, 2009
    Assignees: The Regents of the University of California, Agensys, Inc.
    Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits